By
Ottobock has published its audited 2025 annual report, confirming the preliminary figures released in February and reporting strong double-digit growth across its core business, alongside a proposed dividend of €0.97 per share. The Germany-based prosthetics and orthotics group said core revenues rose 11.7 percent to €1.6 billion, while underlying core EBITDA increased 29.5 percent to €415.3 million and underlying net income climbed 83.2 percent to €177.3 million.
The company described 2025 as a record year, with CEO Oliver Jakobi saying the results reflected Ottobock’s above-market development and the strength of its innovation-led and integrated business model. Ottobock noted that it had already communicated its preliminary 2025 figures and 2026 outlook on 17 February 2026, and that the final annual report now confirms those earlier numbers.
Cash generation also improved. Ottobock reported free cash flow of €228.0 million, up 23.7 percent from 2024, while its dynamic leverage ratio fell to 2.3x, compared with 3.5x a year earlier. The company said the improvement was driven by stronger EBITDA and very good cash flow performance.
From a regional perspective, EMEA remained Ottobock’s largest segment, with revenues rising 12.7 percent to €1,149.2 million. The company attributed that growth mainly to demand for newer products such as the Genium X4 mechatronic prosthetic knee joint, the expansion of the Taleo prosthetic foot portfolio, and continued investment in the Patient Care business. Revenues in the Americas rose 9.5 percent to €346.0 million, while APAC increased 7.4 percent to €104.4 million.
By business category, Ottobock’s Products & Components (B2B) division generated €896.2 million in revenues in 2025, up 14.5 percent year on year, while Patient Care (B2C) revenues reached €703.4 million, an 8.3 percent increase. Products & Components accounted for 53.4 percent of total core revenues, compared with 41.9 percent for Patient Care, underscoring the continued importance of component sales, digital O&P solutions, neuro-orthotics, and bionic exoskeleton-related business within the group’s broader strategy.
For shareholders, the Executive Board and Supervisory Board will propose a dividend of €0.97 per share at the Annual General Meeting on 19 May 2026. According to Ottobock, that represents a 35 percent payout ratio of underlying net income and remains in line with its strategic policy of distributing 30 to 40 percent of underlying net income. If approved, the total payout would amount to €62.1 million.
The 2025 report is also notable because it includes, for the first time, Ottobock’s combined non-financial group report prepared on the basis of the European Sustainability Reporting Standards (ESRS). The company further noted that it has been listed in the Prime Standard since 9 October 2025 and joined the SDAX and TecDAX by the end of 2025, highlighting its growing visibility in public markets following its IPO period.
For the global prosthetics and orthotics sector, the results reinforce Ottobock’s scale and influence across both product manufacturing and patient care delivery. They also show how advanced prosthetic knees, orthotic technologies, digital O&P solutions, and integrated clinic networks continue to shape growth at the top end of the rehabilitation technology market. That said, the annual report also notes that impairment losses and extraordinary expenses related to restructuring, the IPO, and the planned disposal of the Human Mobility business affected group net income after extraordinary items, a reminder that portfolio reshaping remains part of the company’s ongoing strategy.
